People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side-effects, according to a ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...